Aurora Cannabis Inc. has extended its reach in Australia by partnering with Leafio, the wholesale distribution arm of Montu Australia. The deal will place Aurora’s MedReleaf, CraftPlant, Aurora, Whistler Cannabis Co. and IndiMed brands into Leafio’s nationwide supply chain, which serves more than 4,000 pharmacies across the country.
The partnership is a strategic move to deepen Aurora’s presence in a market where it already holds a significant share. Aurora acquired MedReleaf Australia in February 2024, when the company was the second‑largest medical‑cannabis provider in Australia, with an estimated AUD 400 million market share. The new distribution channel is expected to accelerate patient access to Aurora’s TGA‑GMP certified products and to reinforce the company’s “medical‑cannabis‑first” strategy.
Financially, Aurora reported Q2 FY26 net revenue of $90.4 million, up 11% year‑over‑year, and adjusted EBITDA of $15.4 million, a 52% increase from the prior quarter. In Q4 2025 the company posted net revenue of $90.5 million and a net loss of $17.2 million, indicating a 3% revenue rise but a 34% year‑over‑year decline in profitability. The partnership is expected to build on this momentum by expanding Aurora’s distribution footprint without a significant capital outlay, thereby potentially boosting revenue and margin in a high‑margin market.
The deal also leverages Leafio’s clinician‑education focus, which helps navigate the Australian regulatory environment that has seen political pushback against online access to medical cannabis. By integrating its products into Leafio’s established network, Aurora can maintain compliance while expanding reach, a key advantage in a market where regulatory clarity is still evolving.
Management highlighted the strategic fit: CEO Miguel Martin said the partnership would “bolster access to world‑class products and expertise” and support healthcare professionals with educational resources. MedReleaf’s interim managing director Stanley Sack noted the synergy between Aurora’s TGA‑GMP certified products and Leafio’s sector knowledge, while Leafio’s general manager Nicole Le Maistre emphasized the partnership’s potential to deliver meaningful benefits to the region’s medical‑cannabis industry.
No immediate market reaction data were reported for the announcement, but the partnership is positioned to strengthen Aurora’s competitive moat by combining a high‑quality product portfolio with a broad pharmacy network, potentially accelerating revenue growth in a key international market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.